- Conditions
- Suspected or Documented Gram-negative Bacterial Infection
- Interventions
- IMI/REL, Active Control, Oral Switch
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Long Beach, California • San Diego, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sepsis
- Interventions
- Imipenem-relebactam
- Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Obesity, Critical Illness
- Interventions
- Imipenem/Cilastatin/Relebactam 1.25g
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sepsis
- Interventions
- Imipenem, Cilastatin and Relebactam
- Drug
- Lead sponsor
- Joseph L. Kuti, PharmD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
- Interventions
- Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam
- Drug
- Lead sponsor
- Evopoint Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Hartford, Connecticut • Miami, Florida + 7 more
- Conditions
- Cystic Fibrosis, Pneumonia, Bacterial
- Interventions
- Imipenem/Cilastatin/Relebactam
- Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Hartford, Connecticut • Pittsburgh, Pennsylvania
- Conditions
- Suspected or Documented Gram-negative Bacterial Infection
- Interventions
- IMI/REL FDC
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections, Antibiotic Resistant Infection
- Interventions
- Imipenem+Relebactam
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina